Charles Schwab
DMRA

Charles Schwab’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Charles Schwab’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$324K Buy
+12,500
New +$321K ﹤0.01% 3230
2024
Q2 		– Sell
-630
Closed -$12.3K – 3649
2024
Q1 		$12.3K Hold
630
– – ﹤0.01% 3455
2023
Q4 		$11.3K Hold
630
– – ﹤0.01% 3519
2023
Q3 		$11.3K Hold
630
– – ﹤0.01% 3558
2023
Q2 		$39.7K Buy
+630
New +$34.3K ﹤0.01% 3449

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Charles Schwab's DMRA Position: Q1 2026 in Review

Charles Schwab opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2026: 12,500 shares worth $324K. The stake represents ﹤0.01% of the portfolio and ranks #3230 among its holdings. This is a return to the name: Charles Schwab previously reported a position in DMRA as recently as Q1 2024.

Charles Schwab first reported a position in DMRA in Q2 2023 and has held it in 5 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Charles Schwab held 12,500 shares of Damora Therapeutics, Inc. Ordinary Shares worth $324K as of Q1 2026.
  • Damora Therapeutics, Inc. Ordinary Shares was a new Charles Schwab position in Q1 2026.
  • Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3230 holding.
  • Charles Schwab first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q2 2023 and has held it in 5 quarters since.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.